Intended for UK Healthcare Professionals. This website contains promotional content.
Intended for IE Healthcare Professionals. This website contains promotional content.
Report adverse events
EPC® sofosbuvir/velpatasvir 400 mg/100 mg coated tablets
VSV® (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg tablets)
HVN® ledipasvir 90 mg/sofosbuvir 400 mg tablets
HPX®▼ (bulevirtide 2mg)

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page. HEPCLUDEX® (bulevirtide)▼ is subject to additional monitoring

  1. Home >
  2. On-Demand Content >
  3. HDV

Hepatitis delta virus (HDV) On Demand

This page offers you the opportunity to learn about the unique properties of HDV, its natural history and management approaches including the therapeutic landscape. Although HDV is rare, it causes the most severe form of viral hepatitis. Effective strategies for screening, prevention and treatment are therefore very important.1

Hepatitis delta virus (HDV) on demand

Nearly 50 years after HDV discovery: knowns and unknowns

A panel of experts from Italy, England and Scotland assessed the current knowledge and challenges in HDV, with a focus on improving care in the UK

Watch now

A small virus, a big threat

Dr Ivana Carey, Clinical Lecturer in Viral Hepatitis, Kings College London discussed the pathogenesis and prognosis of HDV compared with HBV mono-infection and HBV-HDV-HIV triple infection

Watch now
Hepatitis delta virus (HDV) on demand

Hepatitis delta virus (HDV) on demand

On-demand content and resources covering Hepatitis delta virus (HDV)

Sign up now

References:

  1. Miao Z, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020;221:1677–1687.

UKI-HPX-0047

Date of preparation February 2025